Pharmacy-mediated interchangeability for similar biotherapeutic products

Published on: 25 May 2016

‘Pharmacy-mediated interchangeability’ is defined as a framework permitting substitution of biotherapeutics at the pharmacy level without the consent of the prescribing physician. IFPMA believes there should be a distinction in public health policy between this type of substitution and the type of switching performed under medical supervision. The following policy position developed by IFPMA is intended to inform the relevant pharmacy practice considerations and the more general requirements of a national policy framework.